Unicycive Therapeutics Files 8-K Amendment
Ticker: UNCY · Form: 8-K/A · Filed: Apr 14, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K/A |
| Filed Date | Apr 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement, equity-sale
TL;DR
Unicycive filed an 8-K amendment on April 14, 2025, updating details on material agreements and equity sales from March 13, 2024.
AI Summary
Unicycive Therapeutics, Inc. filed an amendment (8-K/A) on April 14, 2025, to its Form 8-K originally filed on March 13, 2024. This amendment pertains to the entry into a material definitive agreement, unregistered sales of equity securities, amendments to its articles of incorporation or bylaws, and financial statements and exhibits. The original report date was March 13, 2024.
Why It Matters
This filing provides updated or corrected information regarding significant corporate events, including material agreements and equity sales, which are crucial for investors to understand the company's financial and operational status.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings can indicate corrections or updates to previously disclosed material information, which may impact investor perception and stock price.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- March 13, 2024 (date) — Original report date
- April 14, 2025 (date) — Amendment filing date
FAQ
What is the primary purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previously filed Form 8-K, providing updated or corrected information regarding material definitive agreements, unregistered sales of equity securities, amendments to articles of incorporation or bylaws, and financial statements and exhibits.
When was the original Form 8-K filed?
The original Form 8-K was filed on March 13, 2024.
On what date was this amendment (8-K/A) filed?
This amendment (8-K/A) was filed on April 14, 2025.
What specific items are being amended or updated in this filing?
The filing amends information related to the entry into a material definitive agreement, unregistered sales of equity securities, amendments to articles of incorporation or bylaws, and financial statements and exhibits.
What is the principal executive office address for Unicycive Therapeutics, Inc.?
The principal executive office address is 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on April 14, 2025 regarding Unicycive Therapeutics, Inc. (UNCY).